MedCity News

APRIL 9, 2024

The post Which Health Tech Startups Will Present in the Payer/Provider Track of INVEST Pitch Perfect? The finalists for the Payer/Provider track are applying their health tech solutions to addressing burnout and operational efficiency. appeared first on MedCity News.

290

290

Fierce Pharma

OCTOBER 30, 2024

As part of the new budget presented Wednesday by the U.K.’s Biopharma production efforts are set to receive a big boost in the U.K. thanks to a new budget rolled out by the Labour Party following this summer’s general election. |

Manufacturing 263

Manufacturing Biopharma Medical 263

MedCity News

DECEMBER 3, 2024

Keros Therapeutics will present Phase 2 data for the drug, elritercept, at the annual meeting of the American Society of Hematology. Meanwhile, the Takeda deal enables Keros to focus on two wholly owned assets, one of which could compete with a Merck drug approved earlier this year.

Pharmaceutical 299

Pharmaceutical Biopharma Pharma 299

MedCity News

JANUARY 12, 2025

Other STAT6 drug developers include Kymera Therapeutics and Sanofi-partnered Recludix Pharma, which is presenting this week during the J.P. Gilead Sciences is acquiring LEO Pharmas oral small molecule inhibitors of STAT6, a protein key to two validated inflammation pathways. Morgan Healthcare Conference.

Pharma 263

Pharma Healthcare Healthcare Biopharma 263

MedCity News

MAY 12, 2025

Full details from the head-to-head Phase 3 test were presented at the European Congress on Obesity meeting. Eli Lilly reported that in addition to achieving greater reductions in weight, Zepbound-treated patients achieved greater reductions in waist circumference compared to those treated with Novo Nordisks Wegovy.

Patients 245

Patients Biopharma Pharma 245

MedCity News

NOVEMBER 4, 2024

Higher doses of a Viking Therapeutics pill that targets two receptors led to greater weight loss without worsening safety or tolerability, according to Phase 1 results presented during the ObesityWeek conference. Meanwhile, an injectable version of this Viking drug is on track to Phase 3 testing.

Safety 283

Safety Biopharma 283

MedCity News

MAY 30, 2025

The results will be presented Friday during the annual meeting of the American Society of Clinical Oncology. Pfizer drug Braftovi achieved statistically significant and clinically meaningful improvement in overall survival for colorectal cancer patients in a Phase 3 clinical trial.

Leads 232

Leads Patients Biopharma Pharma 232

MedCity News

DECEMBER 5, 2024

Healthcare needs a better way to collect information from all sources, organize it, summarize it and present it to providers in a way that lets them deliver the necessary treatment, confident that the material is sound and verifiable. The post How the Right AI Can Improve Health Risk Assessments appeared first on MedCity News.

Healthcare 305

Healthcare Healthcare Physicians Patients 305

MedCity News

DECEMBER 3, 2024

Incorporating PbD into the software development process of EHR systems presents a strategy to protect information starting from the initial stages of development and, throughout the entire lifecycle of the software. The post Boosting HIPAA Compliance in EHR Systems with Privacy-by-Design appeared first on MedCity News.

308

308

MedCity News

APRIL 24, 2025

The Flagship Pioneering startups approach offers the potential to prevent disease; in cases where disease is already present, Etiome aims to halt or even reverse it. The post Aiming for Earlier Intervention, Flagship Startup Etiome Emerges to Define Biostages of Disease appeared first on MedCity News.

Medicine 236

Medicine Biopharma 236

MedCity News

JANUARY 8, 2024

The word has gained greater urgency in recent years as the consumer trend in healthcare has forced payers, providers and all other kinds of healthcare stakeholders to swear by it.

Healthcare 306

Healthcare Healthcare Retail Biopharma 306

MedCity News

JUNE 1, 2025

The Phase 3 results were presented during the annual meeting of the American Society of Clinical Oncology. The post At ASCO, Merck KGaA Shows How Its Drug Measures Up as Treatment for Rare Type of Tumor appeared first on MedCity News.

Pharma 229

Pharma Medical Biopharma 229

Fierce Pharma

JUNE 14, 2024

Six months after Vertex earned a historic FDA approval for sickle cell d | Six months after Vertex earned a historic FDA approval for sickle cell disease (SCD) gene therapy Casgevy (exa-cel), long-term data is beginning to show the consistent efficacy and durability of the treatment, which is the first ever to be developed using CRISPR gene editing (..)

FDA 263

FDA 263

World of DTC Marketing

JUNE 27, 2025

Influence of Pharma and Medical Liaisons : Pharmaceutical companies and medical science liaisons (MSLs) play an important role in presenting summarized, accurate, and clinically relevant trial data to busy physicians. Peer interactions, discussions with colleagues, and professional forums.

Physicians 244

Physicians Medical science Medical Education 244

Fierce Pharma

JULY 31, 2024

On the heels of game-changing trial results presented at la | On the heels of game-changing trial results presented at last year's ASH meeting, J&J is introducing what it calls a "foundational frontline therapy" in multiple myeloma and at the same time expanding its already impressive presence in the field.

FDA 295

FDA 295

Fierce Pharma

OCTOBER 22, 2024

Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job in a new presentation. Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.

Management 333

Management 333

Fierce Pharma

AUGUST 2, 2024

This week on “The Top Line,” we discuss two studies in HIV research that were presented at the 25th International AIDS | This week on “The Top Line,” we dive into two studies in HIV research that were presented at the 25th International AIDS Conference in Germany.

Patients 268

Patients 268

Fierce Pharma

OCTOBER 16, 2024

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from Gilead Sciences, the company has presented strong results from three real-world studies of its bi-monthly injection for HIV prevention.

Competition 313

Competition 313

MedCity News

AUGUST 26, 2024

With so much hinging on technology that is the subject of so much hype, it is important to understand where AI actually helps at present — and where it most definitely does not. The post The Truth About AI and Healthcare Payer Modernization appeared first on MedCity News.

Healthcare 312

Healthcare Healthcare 312

MedCity News

MARCH 26, 2023

In the EU, there is a widespread distrust of American tech companies, according to a recent conference presentation by an international healthcare lawyer.

Healthcare 359

Healthcare Healthcare 359

MedCity News

SEPTEMBER 10, 2023

Some of the use cases the EHR vendor is exploring include an enhanced search and summarization tool that would present clinicians with a longitudinal view of their patient and a tool that would generate predictive summaries of what a patient’s stay might look like at the time of admission.

Patients 358

Patients Healthcare Healthcare 358

Fierce Pharma

JANUARY 8, 2024

It took Bristol Myers Squibb’s new CEO Chris Boerner 16 minutes into his 24-minute presentation to address the big news the company made last month, with its holiday

320

320

MedCity News

NOVEMBER 16, 2022

The findings were presented at the HLTH conference in Las Vegas. Because of bad digital experiences, 41% of patients have changed providers, the Notable survey discovered.

Patients 312

Patients Medical 312

Fierce Pharma

AUGUST 7, 2024

In its quarterly earnings presentation, the Danish company said that after discussions with the FDA, it has pulled its filing and expects to resubmit in early 2025. Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold.

FDA 314

FDA Patients 314

MedCity News

JANUARY 5, 2024

Check out news from Kismet Health, the University of California at Berkeley’s life science startups, and the companies presenting at the Consumer Technology Association’s pitch contest at CES.

Healthcare 312

Healthcare Healthcare 312

Fierce Pharma

OCTOBER 17, 2023

23 when the full data of MARIPOSA are presented at ESMO 2023. | Editor's note: This is an evolving story. Please check back on Oct. A drug combination from Johnson & Johnson outperformed AstraZeneca’s Tagrisso in slowing the worsening of newly diagnosed lung cancer.

330

330

MedCity News

JULY 19, 2024

It also explores the ethical issues AI in healthcare presents. A new eBook from MedCity News highlights the variety of technologies emerging from AI tech developers across the healthcare landscape from health tech startups to healthcare organizations, biopharma companies, and a medtech giant.

Ethics 299

Ethics Biopharma Healthcare Healthcare 299

Fierce Pharma

APRIL 29, 2024

After last quarter presenting three factors necessary for a more successful launch of hemophilia A gene therapy Roctavian, BioMarin has now added a divestiture to the list of potenti | After last quarter presenting three factors necessary for a more successful launch of hemophilia A gene therapy Roctavian, BioMarin has now added a divestiture to the (..)

Sales 273

Sales Medicine 273

Fierce Pharma

JANUARY 10, 2024

In his first presentation as the new CEO of BioMarin, Alexander Hardy left no doubt about his mission for the rare and genetic disease specialist. | In his first presentation as the new CEO of BioMarin, Alexander Hardy left no doubt about his mission for the rare and genetic disease specialist.

276

276

MedCity News

SEPTEMBER 21, 2023

During a conference presentation on Tuesday, healthcare AI expert Suchi Saria laid out seven AI pitfalls hospitals should look out for — some of these include being duped by Big Tech companies’ marketing strategies and focusing too much on administrative use cases.

Healthcare 328

Healthcare Healthcare Marketing 328

MedCity News

AUGUST 12, 2024

Merck is acquiring a Curon Biopharmaceuticals drug whose encouraging Phase 1 data were presented during the ASCO annual meeting. The pharmaceutical giant sees potential applications of the bispecific antibody in cancer and autoimmune disease.

Pharmaceutical 290

Pharmaceutical Biopharma Pharma 290

MedCity News

JUNE 16, 2024

Palliative care provided by video was equivalent to in-person visits with a clinician, according to study results presented during the recent annual meeting of the American Society of Clinical Oncology. Investigators say these results indicate telehealth can make palliative care accessible to more cancer patients.

Patients 325

Patients Biopharma 325

Fierce Pharma

OCTOBER 18, 2023

22 when the full data of EV-302 are presented at ESMO 2023. | Editor's Note: Please check back on Oct. The results are in for a phase 3 bladder cancer trial assessing the combination of Seagen and Astellas' Padcev, plus Merck's Keytruda, versus standard of care chemotherapy.

324

324

MedCity News

JANUARY 9, 2023

In an interview with MedCity News after his presentation at the J.P. Morgan Healthcare Conference, Wright Lassiter III said while some providers will be considered commodities, his vision for CommonSpirit Health is not to be “at the bottom of the totem pole.”

Healthcare 306

Healthcare Healthcare 306

Fierce Pharma

SEPTEMBER 6, 2024

Nucala is already approved in a range of respiratory conditions, but a COPD nod could present another big opportunity for the drug.

FDA 301

FDA Patients 301

MedCity News

OCTOBER 27, 2023

Seven companies presented their approaches to addressing women’s health. Femtech was the theme of the INVEST Digital Health Pitch Perfect contest in Dallas this week.

289

289

MedCity News

JUNE 2, 2024

The results will be presented Sunday during the annual meeting of the American Society of Clinical Oncology. AstraZeneca’s Tagrisso and Imfinzi helped patients live longer in separate pivotal clinical trials evaluating the drugs in two different types of lung cancer.

Patients 311

Patients Biopharma Pharma 311